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The clustering of cardiovascular risk factors is the rule rather than the exception in the worldwide population: in the general population, around 30-40% of individuals have two or more cardiovascular risk factors. 1, 2 The impact of multiple comorbidities on total risk of cardiovascular disease is enormous: in the INTERHEART study the risk of cardiovascular disease is >40-fold higher when smoking, hypertension, diabetes and dyslipidaemia are present at the same time. 3 This situation is amplified in people with type 2 diabetes: not only are mortality rates for cardiovascular disease much higher in diabetic men when hypertension, hypercholesterolemia or smoking are present, but also they rise more steeply with progressively more unfavourable risk factor status. 4 Furthermore, since diabetes is among the main risk factors for resistant hypertension, 5 the need for multiple blood pressure (BP)-lowering drugs is very common among diabetic patients. Based on this evidence, the present strategy for cardiovascular disease prevention is based on the assessment of global cardiovascular risk assessment, using multivariable prediction models that estimate absolute cardiovascular risk from routinely measured clinical variables; as a consequence, cardiovascular disease prevention guidelines recommend to deliver the most intensive preventive therapies to those at highest global cardiovascular risk, regardless of the relative weight of the single risk factors. 6 However, it is obvious that the cardiovascular protection achieved by drugs is directly proportional to drug compliance. 7 Thus, the concept of the 'polypill', which was proposed initially 15 years ago by Wald and Law, is extremely appealing, since it is well known that adherence is a function of the number of prescribed pills. 8 A recent Cochrane revision of the literature, including a meta-analysis of nine randomized trials and four additional trials, demonstrated that fixeddose combination (FDC) therapy improved adherence to a multi-drug strategy by 33% (26-41%) compared with usual care, whereas the effect on mortality and acute events is still uncertain, because of lack of highquality data. 9 In the present issue of the European Journal of Preventive Cardiology, Janssen and coauthors 10 evaluated the proportion of diabetic individuals at very-high cardiovascular risk in which they were already receiving multiple drug treatment, or in which this treatment would be indicated, in order to estimate the extent of the possible use of FDC therapy. For this study, they took advantage of the SMART (Second Manifestations of ARTerial disease) study, an ongoing prospective cohort at the University Medical Centre Utrecht in The Netherlands, including patients aged 18-80 years with clinically manifest atherosclerotic vascular disease or those at high risk of vascular disease.
In the present analysis, 568 type-2 diabetic patients with clinically manifest vascular disease (mostly coronary artery disease) and 1260 without included in SMART between January 1996 and March 2015 were selected. The prevalent use of two different polypill components was tested: a cardiovascular polypill combination (two BP-lowering drugs, one statin, one antiplatelet drug in the presence of vascular disease) and a diabetic polypill combination (two BP-lowering drugs, one statin, one antidiabetic drug, one antiplatelet drug in the presence of vascular disease).
This study showed a constant increase of the use of the tested multiple drug combinations throughout the study time interval: in diabetic patients without vascular disease the use of the cardiovascular polypill combination increased from 0% to 36% and the use of the diabetic polypill combination increased from 0% to 32% from 1996 to 2015. In diabetic patients with vascular disease, the use of the cardiovascular polypill combination substantially increased to 67% and the use of the diabetic polypill combination increased to 57% in 2014-2015. 10 A substantial improvement in guideline implementation has been also observed in these real-life data, with a treatment gap which was progressively reduced over time, especially in diabetic patients with vascular disease. In this subset of the population at a particularly high cardiovascular risk, the simple substitution of single pills with a FDC may result in a relevant reduction in cardiovascular events, simply due to increased adherence. In a recent analysis comparing the implementation of a cardiovascular polypill (aspirin, statin and angiotensin-converting enzyme (ACE)-inhibitor) compared with multiple monotherapy in adults with a history of myocardial infarction in the UK, the FDC-based therapy proved to be cost-effective: the only improvement in adherence (estimated to be about 20%) was estimated to prevent 15% of fatal and non-fatal cardiovascular events (47 out of 323/1000 patients).
11 Cost-effectiveness of FDC has been demonstrated even in low-middle income countries such as India: interestingly, it appears to be greater in patients with diabetes, 12 further reinforcing the clinical relevance of the present analysis.
Some additional consideration may be given to the drug classes that should be included in the cardiovascular and diabetic polypill. Based on the most used drug classes in the SMART cohort, the authors advocated a cardiovascular polypill constituted by an ACE-inhibitor, a thiazide diuretic and a generic statin for diabetic patients without vascular disease, with the addition of aspirin and beta-blocker to replace the thiazide diuretic in diabetic patients with vascular disease. 10 Indeed, the drug choice recommended is a consequence of historical prescribing habits and may not take into account the most recent evidence and international recommendations. Though it is undoubted that any therapeutic scheme for patients with coronary artery disease must include a beta-blocker if not contraindicated, it is also true that:
1. Forthcoming European Society of Cardiology/ European Society of Hypertension guidelines for hypertension treatment will recommend the association ACE-inhibitor þ calcium channel blocker, preferably in a FDC as first-line, starting treatment. 13 2. Statin efficacy in terms of prevention of cardiovascular events might be superior in combination schemes including a calcium channel blocker to those including a beta-blocker, as suggested by a sub-analysis of the ASCOT study.
14 An increased adherence with two polypill strategies (including lisinopril þ atenolol or lisinopril þ hydrochlorothiazide, aspirin and simvastatin) compared with usual care in individuals with established cardiovascular disease, as well as the cost-effectiveness of this approach, has been recently demonstrated by the UMPIRE (Use of Multidrug Pill In Reducing cardiovascular Events) study. 12 Future studies evaluating the efficacy and the cost-efficacy of calcium channel blocker-based FDC therapies are warranted.
Finally, the results regarding the diabetic polypill should also be commented upon. Among patients selected for this analysis, 80% received additional oral glucose-lowering therapy, which was mainly metformin (73%). Though metformin is still a cornerstone of oral antidiabetic treatment in type-2 diabetes and its cost is absolutely competitive, recent randomized trials suggested a better cardiovascular protection with newer antidiabetic drug classes. 15 Though the use of these expensive drugs in the context a polypill is still premature, we cannot exclude a wider use in the near future.
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